Navigation Links
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
Date:7/1/2009

Single-dose of investigational sustained follicle stimulant achieves similar efficacy to daily injections of follitropin beta given over a one week period in Phase III Study

AMSTERDAM, July 1 /PRNewswire-FirstCall/ -- Schering-Plough Corp., (NYSE: SGP) today announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days. The ENGAGE data was presented along with data from the Phase III ENSURE trial and the Phase II REALIZE trial at the 25th annual meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Amsterdam, The Netherlands.

"The burden of fertility treatment is a major challenge for women experiencing difficulty conceiving," said Thomas Koestler, executive vice president and president, Schering-Plough Research Institute. "Schering-Plough is committed to making fertility treatments easier, and these results demonstrate that corifollitropin alfa in combination with a GnRH antagonist may be an effective treatment that can reduce the number of injections and the length of treatment protocols."

ENGAGE is the largest double-blind fertility agent trial ever performed. The ongoing pregnancy rate, the primary endpoint of the ENGAGE non-inferiority trial, obtained in the 150 mcg corifollitropin alfa treatment arm (38.9 percent per started cycle) was similar to that achieved in patients receiving a daily dose of 200 IU rFSH (follitropin beta) for seven days (38.1 percent per started cycle).(1) ENGAGE also demonstrated that a single injection of 150 mcg corifollitropin alfa achieved similar oocyte and embryo quality compared to a daily dose of 200 IU rFSH given for one week.(2)
'/>"/>

SOURCE Schering-Plough
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Therapure Biopharma to perform fill/finish of nimotuzumab - ... Allan, Chairman and CEO of YM BioSciences Inc. ... Biopharma Inc. today announced the signing of an ... and finish services for nimotuzumab, the humanized monoclonal ... BioSciences Inc., by the Centre of Molecular Immunology ...
(Date:12/17/2009)... allows users to easily find and schedule an appointment for ... health screening, share comments, view personal stories, and connect with ... health screening company’s new site will improve its usability, ... ... OH (PRWEB) December 17, 2009 -- Visitors to Life Line ...
(Date:12/16/2009)... historians, journalists and politicians, and has been recounted everywhere ... Congress: British forces used chemical weapons on Iraqis just ... has never been fully squared with the historical record, ... According to Douglas,s research, forthcoming in the December issue ... such incident ever occurred. , Allegations of chemical ...
(Date:12/16/2009)... death from roadside bombs to freeway crashes. Traumatic injury, ... to 44, often overwhelms the body,s natural blood-clotting process. ... a team led by Erin Lavik, a new Case ... doctoral student, James P. Bertram, built synthetic platelets that ... work is published in Science Translational Medicine ., ...
Breaking Biology Technology:YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract 2YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract 3YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract 4Website Redesign Enhances Global Health Screening Service's Online Presence 2Website Redesign Enhances Global Health Screening Service's Online Presence 3Despite claims, UK did not gas Iraqis in the 1920s, new research finds 2Despite claims, UK did not gas Iraqis in the 1920s, new research finds 3Despite claims, UK did not gas Iraqis in the 1920s, new research finds 4Researchers take the inside route to halt bleeding 2
... (Nasdaq: NTII ) (NTI(R)) today announced ... results of the Viprinex(TM) clinical,trial, the company has ... of acute ischemic stroke. Viprinex was recently studied ... effective in improving patient,outcome when given within six ...
... Antibody Therapeutics BETHESDA, Md., Jan. 13 ... a biopharmaceutical company developing novel, proprietary antibodies for ... today announced the publication of an article in ... revealing a novel signalling function of the epithelial ...
... Inc. a leading provider of Electronic Document Publishing Solutions and Regulatory ... the appointment of Mr. Daniel F. Orfe to Vice President, Global ... oversee Datafarm,s Regulatory Services Group. , ... Marlborough, MA ...
Other Biology Technology:Neurobiological Technologies Announces Suspension of Viprinex Development 2Neurobiological Technologies Announces Suspension of Viprinex Development 3Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling 2Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling 3Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling 4Datafarm, Inc., Announces the Appointment of Daniel F. Orfe to Vice President, Global Regulatory Submission Services 2Datafarm, Inc., Announces the Appointment of Daniel F. Orfe to Vice President, Global Regulatory Submission Services 3Datafarm, Inc., Announces the Appointment of Daniel F. Orfe to Vice President, Global Regulatory Submission Services 4
(Date:12/15/2009)... agreement with the British Society for Research on Ageing ... Biogerontology for an initial period of three ... the Biogerontology editorial board and will acquire ... sponsor the society and provide society members with free ... . , Biogerontology offers a platform for ...
(Date:12/15/2009)... woolly mammoths and ancient American horses may have ... thousand years longer than previously thought. After plucking ... a team of researchers used cutting-edge techniques to ... permafrost samples dated to between 7,600 and 10,500 ... least one population of these now-extinct mammals endured ...
(Date:12/15/2009)... In the near future, consumers can look forward ... such as laptops, PDAs and mobile phones. This ... energy harvesting technologies which are critical elements for ... devices and systems. , Analog IC design is ... energy harvesting. To pre-position the nation in advanced ...
Breaking Biology News(10 mins):Late-surviving megafauna exposed by ancient DNA in frozen soil 2Late-surviving megafauna exposed by ancient DNA in frozen soil 3Late-surviving megafauna exposed by ancient DNA in frozen soil 4NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 3Now Three Big Losers Can Win Big With New OPTIFAST 28R 29 Weight Loss Contest 55608 1Now Three Big Losers Can Win Big With New OPTIFAST 28R 29 Weight Loss Contest 55608 2Hard To Treat Diseases 28HTDS PK 29 46 000 India Doses of Hepatitis A 55605 1Hard To Treat Diseases 28HTDS PK 29 46 000 India Doses of Hepatitis A 55605 2Kristi Yamaguchi Olympic Ice Skater Pushes Seasonal Flu Shots 55601 1Kristi Yamaguchi Olympic Ice Skater Pushes Seasonal Flu Shots 55601 2Kristi Yamaguchi Olympic Ice Skater Pushes Seasonal Flu Shots 55601 3
... of Pennsylvania School of Medicine have identified a link ... (EBV) protein known to be expressed in a number ... by which EBV transforms human B cells from the ... development of B-cell lymphomas. , Erle S. Robertson, PhD, ...
... grow these cells are costly and don't produce cells ... embryonic stem cells, said Shang-Tian Yang, a professor of ... Federal rules forbid the federal funding of research on ... the National Institutes of Health's Human Embryonic Stem Cell ...
... School of Medicine researchers have discovered how the membrane ... how this protein becomes desensitized so that one no ... as an advance online publication by Nature Neuroscience, focused ... is found in many other receptors, including ones involved ...
Other Biology News:Epstein-Barr virus protein crucial to its role in blood cancers 2Researchers devise way to mass-produce embryonic stem cells 2Researchers devise way to mass-produce embryonic stem cells 3
... the macro- and micronutrients as ... (1962) and the vitamins as ... (1968). Preparation Quantity Equivalency: Formulated ... powder per liter of medium. ...
... include: Microarray hybridization chamber assembly (1 ... clamp, thumbscrew) Microarray chamber user guide ... intended to be cleaned and reused. The ... Catalog Oligo Microarray kits and all custom ...
Reported to support murine B lymphocytes, hematopoietic tissue from bone marrow, B cells stimulated with lipopolysaccharide, T lymphocytes, and a variety of hybrid cells....
... peptide whose sequence corresponds to residues 1-18 from rat rab 3D. ... M(1) - A - S - A - S - E ... R - D - A - A - D - Q ... and control experiments with the polyclonal antibody that reacts with this ...
Biology Products: